type in your search and press enter
NILE Study Results Demonstrating Guardant360’s High Concordance to Tissue Testing in Advanced NSCLC Published in Clinical Cancer Research
You May Also Like
Sorrento Therapeutics CEO Dr Ji to Present at LEERINK Partners 7th Global Healthcare Conference on 02/15/18
SAN DIEGO, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced ...
Taiwan Liposome Company Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain
Primary endpoint and key secondary endpoints metTLC599 demonstrated statistically significant improvement over placebo through ...
Aquinox Announces Appointment of Dr. Kelvin Neu and Dr. Richard Levy to Board of Directors
VANCOUVER, British Columbia, March 27, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), ...